Stereotactic body radiation therapy provides local control in pediatric cancer patients

Posted on

Stereotactic body radiation therapy (SBRT) appears to provide durable local control with minimal severe toxicities in pediatric and adolescent/young adult (AYA) patients with cancer, according to a study.

Researchers identified 9 published studies with primary outcomes of 1-year and 2-year local control and incidence of acute and late grade 3 to 5 toxicities, with secondary outcomes of 1-year overall survival and progression-free survival.

Included were 142 pediatric and AYA patients with 217 lesions treated with SBRT.

The estimated local control rates for 1- and 2-years were 83.5% and 74.0%, respectively.

The estimated rate of acute and late grade 3 to 5 toxicities was 75.4% and 27.1%, respectively. The estimated 1-year OS and PFS rates were 75.4% and 27.1%, respectively.

In sarcoma-predominant cohorts, dose escalation may potentially improve local control without an increase in toxicity.

Dose escalation may result in improved LC for sarcoma-predominant cohorts without a subsequent increase in toxicity.

Singh R, Valluri A, Didwania P, et al. Efficacy and Safety of Stereotactic Body Radiation Therapy for Pediatric Malignancies: The LITE-SABR Systematic Review and Meta-Analysis. Adv Radiat Oncol. 2023;8(2):101123. doi: 10.1016/j.adro.2022.101123. PMID: 36845622; PMCID: PMC9943773.